Just a few years ago, gene editing was one of the hottest investment themes on Wall Street.
Then reality set in.
Clinical trials took longer than expected. Regulatory approvals moved at their usual deliberate pace. Investors who expected overnight breakthroughs grew impatient, and biotech stocks were hit hard.
Many assumed the story was over.
But an interesting thing happened last week.
Scribe Therapeutics (SCTX), a clinical-stage gene editing company co-founded by Nobel Prize winner Jennifer Doudna, raised nearly $129 million in its initial public offering. The offering was increased in size, priced at the top of its expected range, and shares surged on their first day of trading. Even more telling, Scribe became the first gene-editing company to complete an IPO in more than two years, signaling renewed investor interest in the sector.
That doesn’t mean gene editing is suddenly “back.”
But it does suggest investors are beginning to recognize something that scientists have known all along.
The innovation never stopped.
That’s an important distinction.
Five years ago, investors were buying gene-editing companies based largely on what the technology might accomplish someday. Expectations ran far ahead of reality, and stock prices reflected years of future success before many companies had even generated meaningful clinical data.
Eventually, those expectations came crashing back to earth.
The science, however, kept moving forward.
Today, gene editing is no longer just a promising concept confined to university laboratories. The first CRISPR-based therapies have reached patients. Researchers are developing more precise technologies such as base editing and prime editing. Companies are expanding beyond rare diseases into much larger markets like cardiovascular disease, autoimmune disorders, and cancer.
That’s exactly what makes Scribe so interesting.
Rather than focusing on an ultra-rare genetic condition, the company’s lead program targets PCSK9, a well-known cholesterol pathway linked to heart disease. Its approach aims to reduce LDL cholesterol without permanently altering a patient’s DNA, potentially opening the door to preventive treatments for millions of people instead of thousands.
At the same time, artificial intelligence is accelerating nearly every stage of drug development.
AI is helping researchers identify promising drug targets faster, predict how proteins behave, design more effective therapies, and analyze enormous genetic datasets in ways that simply weren’t possible a decade ago. What once took years can increasingly be accomplished in months.
Large pharmaceutical companies have taken notice.
Over the past two years, licensing agreements, strategic partnerships, and acquisitions across biotechnology have accelerated as drugmakers search for the next generation of blockbuster therapies. They understand that developing every breakthrough internally isn’t practical. Often, the fastest path is partnering with - or acquiring - the companies already pushing the science forward.
That creates a very different backdrop than we saw during the speculative biotech boom a few years ago.
Back then, investors were chasing possibilities.
Today, they’re increasingly investing in clinical data, stronger pipelines, and businesses that have moved much closer to commercialization.
Does that mean every gene-editing company will succeed?
Of course not.
Drug development has always been a high-risk business. Clinical setbacks and failed trials will remain part of the investment landscape.
But history also shows that the biggest opportunities often emerge after expectations have been reset.
The headlines fade.
The speculative money leaves.
The technology quietly matures.
Eventually, investors realize the revolution never stopped - they just stopped paying attention.
I believe gene editing is entering that stage today.
Where Investors Can Look Today
The good news is that investors no longer have to speculate on whether gene editing will work. Today there are publicly traded companies leading the field, along with large pharmaceutical companies that have already brought gene-editing therapies to patients.
Some of the largest pure-play gene-editing companies include:
· CRISPR Therapeutics (CRSP) – Co-developer of the first FDA-approved CRISPR gene-editing therapy and one of the pioneers in the field.
· Beam Therapeutics (BEAM) – Leader in next-generation base editing technology, designed to make more precise genetic changes.
Investors should also remember that some of the biggest beneficiaries aren’t pure-play genetic companies.
Vertex Pharmaceuticals (VRTX) partnered with CRISPR Therapeutics to develop Casgevy, the world’s first FDA-approved CRISPR-based gene-editing therapy for sickle cell disease and transfusion-dependent beta thalassemia.
Meanwhile, pharmaceutical giants including Eli Lilly (LLY), Pfizer (PFE), Regeneron (REGN), and AstraZeneca (AZN) have all committed billions of dollars through partnerships, licensing agreements, and acquisitions to expand their presence in gene-editing and genomic medicine.
Tomorrow, we’ll look at another technology that became a punchline after the hype faded: the metaverse. While most people think it disappeared, it’s quietly becoming one of the foundational technologies behind artificial intelligence, robotics, and the factories of the future.
Here’s to the future,
Matt McCall
Editor, Market Insights
